New Research Suggests Bone Loss More Likely Among Consistent PrEP Users
According to new research presented at the Conference on Retroviruses and Opportunistic Infections, people taking tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) drugs specifically for PrEP experienced bone …
New Research Suggests Bone Loss More Likely Among Consistent PrEP Users Read More »
